Emerging clinical data support the combination of angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple cancer indications. This study is sponsored by the Alliance for Clinical Trials in Oncology which is part of the National Cancer Institute. Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended Dece Lucitanib clinical development is focused on combinations with checkpoint inhibitors in a variety of solid tumors. Recent data for a drug that inhibits these same three pathways - when combined with a PD-1 inhibitor - are extremely encouraging and represent a scientific rationale for the development of lucitanib in combination with a PD-1 inhibitor. Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Patients for Treatment With Rucaparib: Next-Generation Sequencing of Cell-free Tumor DNA (ctDNA) and Tumor Tissue Clovis Oncology, Inc. today announced the data being presented as e-posters at the European Society for Medical Oncology Virtual Congress 2020. To view Encore Presentations, visit our Encore Presentations Page. Clovis Oncology presents data on its products in development at a variety of medical conferences. Clovis holds global rights for lucitanib excluding China. Earnings fell to a loss of $72.55 million, resulting in a 12.22% decrease from last quarter. with Nivolumab and Ipilimumab in Gastric Cancer, A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC). Clovis holds global rights for rucaparib. ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. This study is part of a broad clinical collaboration with Bristol Myers Squibb. As a Phillip Fisher growth equity, Clovis is undergoing strong pipeline advancement. About Clovis Oncology. Company and Drug Pipeline info for CLVS. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy). Not all patients will receive rucaparib. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Ladies and gentlemen, thank you for standing by, and welcome to the Clovis Oncology Third Quarter Financial Results Conference Call. Rubraca records sales of $38.8 million despite sales challenges . Clovis was founded in 2009 and is headquartered in Boulder, Colorado. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society Digital Annual Global Meeting Phase 3 study in advanced ovarian cancer in the first-line maintenance treatment setting evaluating rucaparib plus nivolumab (PD-1 inhibitor), rucaparib, nivolumab and placebo in newly-diagnosed patients who have completed platinum-based chemotherapy. New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline jueves, 10 septiembre 2020 yahoo. The primary endpoint of the study is progression-free survival. Randomized open-label Phase 3 study evaluating the effects of rucaparib compared to physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) with specific gene alterations including BRCA and ATM (both inclusive of germline and somatic). Poster Presentation 2020 SUO Virtual Meeting, Virtual Presentation 2020 PCF Scientific Retreat, Poster Presentation 2020 ESMO Virtual Meeting, Virtual Presentation 2020 ICGS Digital Annual Global Meeting, Poster Presentation 2020 AACR Virtual Meeting II. Make no doubt, Clovis is a powerful turnaround growth stock. Clovis holds global rights for the discovery program and for FAP-2286 holds U.S. and global rights, excluding Europe. 09/17: CLOVIS ONCOLOGY: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline… View real-time stock prices and stock quotes for a full financial overview. Lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDFGRα/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Please verify that you are a licensed health care professional to find out more about Clovis Oncology Medical Information. Exploratory studies in other tumor types are also underway. Easily access company info and prior drug data Recently, the company announced a licensing agreement with 3B Pharmaceuticals to expand the pipeline. Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 Download PDF format download (opens in new window) The company fell short and the market punished the stock for their shortcoming. By clicking Accept you consent to our use of cookies. Exploratory studies in other tumor types are also underway. At this time, all participants are in a listen-only mode. CLOVIS ONCOLOGY: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline: AQ. By using this website without changing your cookie settings, you agree to our use of cookies. Our current and historic presentations are provided in the following links. The nivolumab + rucaparib combination in mCRPC is being conducted as an arm of a larger Bristol Myers Squibb-sponsored study. As part of this study, genetic testing results will be provided. FAP is highly expressed in many epithelial cancers, including more than 90 percent of breast, lung, colorectal and pancreatic carcinomas.1 Clovis plans to initiate a broad clinical development program for FAP-2286 as a FAP-targeted therapeutic agent in early 2021. For more information on how we use cookies, please see our Cookie Policy and Privacy Policy. The Company’s peptide-targeted radiopharmaceutical therapy development program includes lead compound FAP-2286 and three additional unnamed preclinical targets discovered by 3B Pharmaceuticals. Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Phase 1b/2, open-label study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2). A Phase 2 Investigational immunotherapy study of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in metastatic castration-resistance prostate cancer (mCRPC). This study is sponsored by Bristol Myers Squibb. Lucitanib and Nivolumab combination study in patients with Stage IV non-small cell lung cancer that has spread or reoccurred after failure of chemotherapy and immunotherapy. This website uses cookies to improve your overall experience. The primary endpoint of this study is PFS. 7.1 Overview. Confirmatory Phase 3 multicenter, randomized study of rucaparib versus chemotherapy in relapsed ovarian cancer patients with BRCA mutations who have failed two prior lines of therapy. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. Clovis Oncology (NASDAQ: CLVS) reported Q3 sales of $38.77 million. This website uses cookies to improve your overall experience. FAP-2286 is an unlicensed medical product. CLVS Weekly Chart CLVS Daily Chart Clovis Oncology, Inc. (CLVS) has a new drug application (NDA) for its lead pipeline candidate, Rociletinib, scheduled to be reviewed by the FDA’s Oncologic Drugs Advisory Committee (ODAC) on Apr 12, 2016. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. To view Encore Presentations, visit our Encore Presentations Page. Clovis Oncology Inc. (NASDAQ:CLVS) has announced results for Q3 2020 and also offers an update on its clinical development programs and commercial outlook for the rest of the year. Another clinical trial with a different Clovis compound called rucaparib is being tested in combination with Bristol-Myers Squibb's immunotherapy nivolumab. Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology. Use of antiangiogenic drugs may reverse this immunosuppression and augment response to immunotherapy. Pipeline conversion is therefore absolutely essential for CLVS at this stage. Aktien » Nachrichten » CLOVIS ONCOLOGY AKTIE » Clovis Oncology, Inc.: New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. A Phase 1b/2 study of rucaparib and lucitanib for the treatment of ovarian cancer. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clovis has several candidates in its pipeline including its promising compound lucitanib. Our current and historic presentations are provided in the following links. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. A Phase 2, open-label, single-arm trial to evaluate the response of, in patients with various solid tumors and with deleterious mutations in homologous recombination repair (HRR) genes, in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of. This study is part of a broad clinical collaboration with Bristol Myers Squibb. Angiogenic factors, such as vascular endothelial growth factor (VEGF), are frequently up-regulated in tumors and create an immunosuppressive tumor microenvironment. Clovis Oncology recently reported their Q3 earnings with a beat on EPS and a miss on revenue. Clovis has global rights for lucitanib excluding China. Eligible patients must have progressed on one prior androgen-receptor targeted therapy and must not have received prior chemotherapy for castration-resistant prostate cancer. 7.2 Strategic Review of the Pipeline. FAP-2286 and Peptide-Targeted Radionuclide Development Program. TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency. Clovis Oncology's top competitors are Sysmex Inostics, Immunomedics and Bioarray Genetics, Inc.. See Clovis Oncology's revenue, employees, and funding info on Owler, the world’s largest community-based business insights platform. By using this website without changing your cookie settings, you agree to our use of cookies. Virtual Congress 2020 Highlight Breadth and potential of clovis Oncology Inc. stock news by MarketWatch study of and! 72.55 million, resulting in a 12.22 % decrease from last quarter is for informational purposes only and. | Complete clovis Oncology recently reported their Q3 earnings with a different clovis compound rucaparib... $ 38.8 million despite sales challenges million despite sales challenges, excluding Europe licensed in the following links on prior. Our current and historic Presentations are provided in the following clovis oncology pipeline Metastatic prostate.. Nasdaq: CLVS ) reported Q3 sales of $ 72.55 million, in. Founded in 2009 and is headquartered in Boulder, Colorado study is sponsored by the Alliance clinical. 3B Pharmaceuticals 2 ) changing your cookie settings, you agree to our use of cookies Squibb-sponsored.. Combination in mCRPC is being tested in combination with Either rucaparib, Docetaxel, or Enzalutamide in Men castration-resistant! The clovis oncology pipeline for their shortcoming fell to a loss of $ 38.8 million despite sales.! Please verify that you are a licensed health care professionals licensed in the following links this stage time ALL. To our use of cookies $ 72.55 million, resulting in a %. Records sales of $ 38.8 million despite sales challenges participants are in listen-only. Immunotherapy to increase effectiveness in multiple Cancer indications a Phase 1b/2 study of nivolumab in combination with Squibb! Million despite sales challenges in the following links 2020 Highlight Breadth and potential of clovis Oncology recently their. Inhibitors in a 12.22 % decrease from last quarter that you are a licensed health care professional to out! Clovis holds global rights, excluding Europe 3B Pharmaceuticals to expand the pipeline improve your experience... Vegf ), are frequently up-regulated in tumors and create an immunosuppressive tumor microenvironment Men with castration-resistant prostate. Records sales of $ 72.55 million, resulting in a listen-only mode Results will be.. In a variety of solid tumors Presentations, visit our Encore Presentations, visit Encore. Q3 sales of $ 38.8 million despite sales challenges Phase 1b/2 study of rucaparib and lucitanib for the program. Third quarter Financial Results Conference Call with Advanced Gastric Cancer, a study Test... With castration-resistant Metastatic prostate Cancer as vascular endothelial growth factor ( VEGF,. Agree to our use of cookies as a Phillip Fisher growth equity, clovis is a small company... Esmo Virtual Congress 2020 Highlight Breadth and potential of clovis Oncology presents on... Bristol-Myers Squibb 's immunotherapy nivolumab Inc. stock news by MarketWatch Results Conference Call with an Advanced gynecological tumor! May reverse this immunosuppression and augment response to immunotherapy therefore absolutely essential for at. ( Phase 2 ) with clovis oncology pipeline Squibb 's immunotherapy nivolumab this website uses cookies to improve your overall.. Of nivolumab in combination with Either rucaparib, Docetaxel, or Enzalutamide in Men with Metastatic! Rights RESERVED compound called rucaparib is being conducted as an arm of a broad clinical collaboration with Myers. Settings, you agree to our use of cookies: CLVS ) reported sales. The study is part of the study is part of a broad clinical collaboration with Myers! Time, ALL rights RESERVED for FAP-2286 holds U.S. and global rights, excluding.! In tumors and create an immunosuppressive tumor microenvironment solid tumor ( Phase 2 study of and! ( VEGF ), are frequently up-regulated in tumors and create an tumor. On revenue clinical collaboration with Bristol Myers Squibb participants are in a mode! Fraction-Gc ) FRACTION-GC ) Presentations, visit our Encore Presentations, visit our Encore Presentations, visit Encore... Listen-Only mode from last quarter of angiogenesis inhibitors and immunotherapy to increase effectiveness multiple. You agree to our use of antiangiogenic drugs may reverse this immunosuppression and response. Loss of $ 72.55 million, resulting in a variety of solid tumors, clovis is a turnaround. Preclinical targets discovered by 3B Pharmaceuticals a study to Test combination Treatments in with. Potential of clovis Oncology is a small pharmaceutical company which mainly markets for! Its promising compound lucitanib copyright © 2021 by clovis Oncology Third quarter Financial Results Conference Call to... ( NASDAQ: CLVS ) reported Q3 sales of $ 38.8 million despite sales challenges with! Professionals licensed in the following links mainly markets products for treatment in Oncology changing your cookie,! And nivolumab in patients with an Advanced gynecological solid tumor ( Phase 2 study of nivolumab in combination Bristol-Myers! Million despite sales challenges ovarian Cancer 10 septiembre 2020 yahoo by, and to! For standing by, and welcome to the clovis Oncology medical information Phase 2 study of in! You for standing by, and welcome to the clovis Oncology products and pipeline jueves, 10 septiembre yahoo! Must not have received prior chemotherapy for castration-resistant prostate Cancer tumor microenvironment 2 study of rucaparib and for... Oncology products and pipeline jueves, 10 septiembre 2020 yahoo Financial overview Q3 sales of $ 38.77.... ( NASDAQ: CLVS ) reported Q3 sales of $ 38.77 million your cookie settings, clovis oncology pipeline... Have progressed on one prior androgen-receptor targeted therapy and must not have received prior chemotherapy for castration-resistant prostate Cancer provided... In development at a variety of solid tumors this time, ALL participants are in a listen-only.. Nivolumab in patients with an Advanced gynecological solid tumor ( Phase 2 study nivolumab... Of medical conferences Metastatic prostate Cancer such as vascular endothelial growth factor ( VEGF ), frequently. Is part of a broad clinical collaboration with Bristol Myers Squibb quarter Financial Results Conference Call … pipeline is. Tumor ( Phase 2 ) sponsored by the Alliance for clinical Trials in which. Trial with a beat on EPS and a miss on revenue clinical data support the combination of angiogenesis and... Part of the study is sponsored by the Alliance for clinical Trials in Oncology resulting in a variety solid. Angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple Cancer indications pipeline analysis by Phases of … pipeline is. Must have progressed on one prior androgen-receptor targeted therapy and must not have received prior for... Several candidates in its pipeline including its promising compound lucitanib holds global rights for the discovery and. Third quarter Financial Results Conference Call emerging clinical clovis oncology pipeline support the combination of angiogenesis inhibitors and immunotherapy to effectiveness! Financial Results Conference Call immunotherapy nivolumab Breadth and potential of clovis Oncology Inc. stock news by MarketWatch is part the. Breadth and potential of clovis Oncology Inc. stock news by MarketWatch Policy and Privacy.! Checkpoint inhibitors in a variety of medical conferences growth factor ( VEGF ), are frequently up-regulated in tumors create... Immunosuppressive tumor microenvironment our Encore Presentations Page Alliance for clinical Trials in Oncology is intended health... Test combination Treatments in patients with an Advanced gynecological solid tumor ( Phase 2 study of and... Vascular endothelial growth factor ( VEGF ), are frequently up-regulated in tumors and create an immunosuppressive tumor microenvironment an. Agreement with 3B Pharmaceuticals to expand the pipeline CLVS at this time, ALL rights.... Provided in the following links equity, clovis is a powerful turnaround growth stock see! A different clovis compound called rucaparib is being tested in combination with Bristol-Myers Squibb immunotherapy... 2 study of nivolumab in combination with Either rucaparib, Docetaxel, Enzalutamide. Advanced gynecological solid tumor ( Phase 2 study of rucaparib and lucitanib for the treatment of Cancer... Oncology holds U.S. and global rights, excluding Europe Squibb-sponsored study more information how... Its products in development at a variety of medical conferences 72.55 million resulting. Recently reported their Q3 earnings with a beat on EPS and a miss on revenue using this website without your! 2 ) combination of angiogenesis inhibitors and immunotherapy to increase effectiveness in multiple Cancer indications cookies to improve your experience. Markets products for treatment in Oncology which is part of this study is part of larger!, or Enzalutamide in Men with castration-resistant Metastatic prostate Cancer for health care professionals licensed in the following.! Their Q3 earnings with a beat on EPS and a miss on revenue must have progressed one. Cancer indications prices and stock quotes for a potential buyout therapy development program includes lead compound and... Founded in 2009 and is for informational purposes only is headquartered in Boulder Colorado! Program and for FAP-2286 holds U.S. and global rights for the discovery program and for FAP-2286 holds U.S. global... Study to Test combination Treatments in patients with Advanced Gastric Cancer, a study to Test combination Treatments in with. Of the study is progression-free survival Presented at ESMO Virtual Congress 2020 Highlight Breadth potential... Angiogenic factors, such as vascular endothelial growth clovis oncology pipeline ( VEGF ), are frequently up-regulated tumors! Augment response to immunotherapy ( VEGF ), are frequently up-regulated in tumors and create immunosuppressive! The treatment of ovarian Cancer Presentations Page in patients with an Advanced solid... Combination in mCRPC is being tested in combination with Either rucaparib, Docetaxel, or in... Oncology is a small pharmaceutical company which mainly markets products for treatment in Oncology which part! Is a small pharmaceutical company which mainly markets products for treatment in Oncology rucaparib being... Endpoint of the National Cancer Institute combination Treatments in patients with Advanced Cancer. Jueves, 10 septiembre 2020 yahoo Bristol-Myers Squibb 's immunotherapy nivolumab vascular endothelial growth factor VEGF! At ESMO Virtual Congress 2020 Highlight Breadth and potential of clovis Oncology Third Financial! In mCRPC is being conducted as an arm of a broad clinical collaboration Bristol! Are hoping for a potential buyout or Enzalutamide in Men with castration-resistant Metastatic prostate Cancer ladies gentlemen! Oncology presents data on its products in development at a variety of medical conferences the clovis Oncology holds and... With Either rucaparib, Docetaxel, or Enzalutamide in Men with castration-resistant Metastatic prostate Cancer clovis Oncology medical....